<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220727055567N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-08-12</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of fentanyl in reducing pain after jaw surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparing effects of local injection of bupivacaine with and without fentanyl at the site of surgery in open reduction mandibular surgeries on acute pain intensity and opioid requirement: a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65112</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random sampling will be done among the patients referred to the maxillofacial surgery department of Imam Reza Hospital in Tabriz who is eligible for the study. The randomization method is simple and its unit is the individual. Our tool for randomizing is the random number table. Accordingly, the type of treatment is marked with the code A (bupivacaine with fentanyl) and B (bupivacaine without fentanyl) and will be placed inside the sealed envelopes; Then the envelopes will be placed in a bag and mixed. After that, it will be randomly chosen from the bag and upon viewing the code, the treatment will be given to the patient. None of the patients will be informed about the treatment of another patient, Blinding description: This study is double-blind, so patients do not know which group they will be in. The researcher who must enter data into the checklist will not know which intervention was conducted. Patients are aware of the existence of two types of treatment, but they do not know which group they belong to.</study_design>
      <phase>2</phase>
      <hc_freetext>Fracture of mandible.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After the surgery is completed and the sutures are applied, 2 cc of Bupivacaine solution (Exir Company-Iran) 0.5% (5 mg/ml) along with 25 micrograms of fentanyl routinely used in the hospital will be injected into the surgical site through an insulin syringe. After discharge from recovery, patients' pain will be measured by a ten-point VAS scale for 24 hours every four hours. Also, the amount of opioid medication needed based on milligrams of pethidine will also be recorded for patients. If the pain intensity of the patients is higher than 5, pethidine will be injected intramuscularly at the rate of 1 mg/kg. Intervention 2: Control group: After the surgery is completed and the sutures are applied, 2 cc of Bupivacaine solution (Exir Company-Iran) 0.5% (5 mg/ml) will be injected into the surgical site by an insulin syringe. After discharge from recovery, patients' pain will be measured by a ten-point VAS scale for 24 hours every four hours. Also, the amount of opioid medication needed based on milligrams of pethidine will also be recorded for patients. If the pain intensity of the patients is higher than 5, pethidine will be injected intramuscularly at the rate of 1 mg/kg.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saeed Nezafati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht St., Tabriz University of Medical Sciences</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 44 3344 4598</telephone>
        <email>nezaf2000@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Saeed Nezafati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht St., Tabriz University of Medical Sciences</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 44 3344 4598</telephone>
        <email>nezaf2000@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate patients for open mandibular surgery
Age above 18 years
Duration of surgery less than 4 hours
Candidate patients for general anesthesia
Consent to jaw fixation</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unwillingness to cooperate in the study
The occurrence of any complications that prevent participation in the study
Hypersensitivity to fentanyl, bupivacaine, and other drugs
The patient's lack of satisfaction with intermaxillary fixation after the operation
Existence of underlying disease and confounding factor such as: hemorrhagic diseases and coagulopathy, kidney and liver diseases, mental and neurological diseases, obstructive lung diseases, hemostatic disorders and dialysis in patients
Addiction to drugs and psychoactive substances and history of drug abuse
The presence of infection in the operation site
History of taking antidepressants and sedatives and any medicine that changes the perception of pain</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S02.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of mandible</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After the surgery is completed and the sutures are applied, 2 cc of Bupivacaine solution (Exir Company-Iran) 0.5% (5 mg/ml) along with 25 micrograms of fentanyl routinely used in the hospital will be injected into the surgical site through an insulin syringe. After discharge from recovery, patients' pain will be measured by a ten-point VAS scale for 24 hours every four hours. Also, the amount of opioid medication needed based on milligrams of pethidine will also be recorded for patients. If the pain intensity of the patients is higher than 5, pethidine will be injected intramuscularly at the rate of 1 mg/kg.</i_keyword>
      <i_keyword>Control group: After the surgery is completed and the sutures are applied, 2 cc of Bupivacaine solution (Exir Company-Iran) 0.5% (5 mg/ml) will be injected into the surgical site by an insulin syringe. After discharge from recovery, patients' pain will be measured by a ten-point VAS scale for 24 hours every four hours. Also, the amount of opioid medication needed based on milligrams of pethidine will also be recorded for patients. If the pain intensity of the patients is higher than 5, pethidine will be injected intramuscularly at the rate of 1 mg/kg.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of pain. Timepoint: Every four hours for 24 hours after surgery. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The amount of opioid use. Timepoint: Every four hours for 24 hours after surgery. Method of measurement: After surgery, the pain level is measured every four hours for 24 hours. If VAS is higher than 5, Pethidine (Exir Company-Iran) will be injected intramuscularly at the rate of 1 mg/kg. After four hours, if the pain repeats, Pethidine injection at the rate of 1 mg/kg will be repeated. The number of times the patient needs pethidine in twenty-four hours will be recorded.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-27</approval_date>
        <contact_name>كميته اخلاق دانشگاه علوم پزشکی تبریز</contact_name>
        <contact_address>Golgasht St., Tabriz University of Medical Sciences Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
